ATUM Appoints Industry Veteran Gavin Barnard, Ph.D., as Chief Scientific Officer
As CSO,
- Hit-to-Lead Services: increasing drug candidate assessment by in silico modelling, small scale expression with developability analytics and AI-guided sequence optimization.
- Cell Line Development: maintaining the growth of ATUM's Leap-In Transposase technology, with over 50 INDs now filed.
- Complex Modalities Roadmap: further enhancing ATUM's service offerings in support of more complex modalities such as multispecifics and ADCs.
"I am delighted to welcome Gavin to ATUM," said
"I have seen firsthand the transformative power of ATUM's technology to solve the industry's most pressing bottlenecks," said
About ATUM
ATUM is a fully integrated biotechnology contract research organization that provides services for gene design, protein engineering, and cell line development. By combining machine learning, synthetic biology, and proprietary expression technologies, ATUM helps partners worldwide transform digital sequences into clinical reality. ATUM is headquartered in
View original content to download multimedia:https://www.prnewswire.com/news-releases/atum-appoints-industry-veteran-gavin-barnard-phd-as-chief-scientific-officer-302743989.html
SOURCE ATUM
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- ONEOK Announces Cash Tender Offers in Connection with $5 Billion Debt Repayment Plan
- Top 5 Crypto Altcoins for Altseason: LINK, SOL, ETH, TRX and MemeToro Enter the Conversation as Traders Seek New Upside
- PG&E Statement on Senate Bill 492
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share